Ken Griffin Amarin Corp Plcuk Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Citadel Advisors LLC holds 64,900 shares of AMRN stock, worth $39,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,900

Previous 73,700 11.94%

Holding current value

$39,589

Previous $46,000 32.61%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.44 - $0.63 $24,714 - $35,386	56,169 Added 32.33%	229,894 $110,000
Q3 2024 Nov 14, 2024	BUY	$0.57 - $0.8 $99,023 - $138,980	173,725 New	173,725 $109,000
Q1 2024 May 15, 2024	SELL	$0.82 - $1.35 $634,478 - $1.04 Million	-773,754 Reduced 56.62%	592,779 $527,000
Q4 2023 Feb 14, 2024	BUY	$0.66 - $0.91 $897,247 - $1.24 Million	1,359,466 Added 19236.82%	1,366,533 $1.19 Million
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.43 $649,570 - $1.09 Million	-764,201 Reduced 99.08%	7,067 $6,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.49 $4.87 Million - $6.48 Million	-4,349,377 Reduced 84.94%	771,268 $917,000
Q1 2023 May 15, 2023	BUY	$1.19 - $2.19 $2.42 Million - $4.45 Million	2,030,845 Added 65.73%	5,120,645 $7.68 Million
Q4 2022 Feb 14, 2023	BUY	$1.07 - $1.34 $2.56 Million - $3.21 Million	2,396,226 Added 345.49%	3,089,800 $3.74 Million
Q3 2022 Nov 14, 2022	SELL	$1.09 - $1.67 $597,426 - $915,323	-548,098 Reduced 44.14%	693,574 $756,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $3.69 $1.32 Million - $4.3 Million	-1,164,140 Reduced 48.39%	1,241,672 $1.85 Million
Q1 2022 May 16, 2022	BUY	$2.85 - $3.73 $3.45 Million - $4.52 Million	1,211,432 Added 101.43%	2,405,812 $7.92 Million
Q4 2021 Feb 14, 2022	SELL	$3.24 - $5.18 $194,756 - $311,369	-60,110 Reduced 4.79%	1,194,380 $4.03 Million
Q3 2021 Nov 15, 2021	BUY	$3.94 - $5.84 $795,801 - $1.18 Million	201,980 Added 19.19%	1,254,490 $6.4 Million
Q2 2021 Aug 16, 2021	SELL	$4.26 - $6.5 $7.3 Million - $11.1 Million	-1,713,454 Reduced 61.95%	1,052,510 $4.61 Million
Q1 2021 May 17, 2021	BUY	$5.03 - $8.8 $5.12 Million - $8.96 Million	1,017,908 Added 58.23%	2,765,964 $17.2 Million
Q4 2020 Feb 16, 2021	SELL	$4.04 - $5.31 $521,499 - $685,436	-129,084 Reduced 6.88%	1,748,056 $8.55 Million
Q3 2020 Nov 16, 2020	BUY	$3.64 - $7.76 $4.62 Million - $9.84 Million	1,268,603 Added 208.47%	1,877,140 $7.9 Million
Q2 2020 Aug 14, 2020	SELL	$4.78 - $8.26 $6.26 Million - $10.8 Million	-1,308,645 Reduced 68.26%	608,537 $4.21 Million
Q1 2020 May 15, 2020	SELL	$4.0 - $21.53 $2.84 Million - $15.3 Million	-709,505 Reduced 27.01%	1,917,182 $7.67 Million
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $5.2 Million - $9 Million	373,164 Added 16.56%	2,626,687 $56.3 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $31.1 Million - $51.9 Million	2,241,531 Added 18691.89%	2,253,523 $34.2 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $6.92 Million - $8.72 Million	-425,128 Reduced 97.26%	11,992 $233,000
Q1 2019 May 15, 2019	BUY	$12.61 - $22.33 $292,047 - $517,162	23,160 Added 5.59%	437,120 $0
Q4 2018 Feb 14, 2019	SELL	$12.41 - $22.98 $11.6 Million - $21.4 Million	-931,183 Reduced 69.23%	413,960 $5.63 Million
Q3 2018 Nov 13, 2018	BUY	$2.45 - $16.27 $706,109 - $4.69 Million	288,208 Added 27.27%	1,345,143 $0
Q2 2018 Aug 10, 2018	BUY	$2.68 - $3.48 $2.21 Million - $2.88 Million	826,161 Added 358.0%	1,056,935 $0
Q1 2018 May 11, 2018	SELL	$2.99 - $4.44 $251,566 - $373,563	-84,136 Reduced 26.72%	230,774 $695,000
Q4 2017 Feb 09, 2018	SELL	$3.06 - $4.09 $20,453 - $27,337	-6,684 Reduced 2.08%	314,910 $1.26 Million
Q3 2017 Nov 09, 2017	BUY	$3.03 - $3.72 $974,429 - $1.2 Million	321,594	321,594 $1.13 Million

Others Institutions Holding AMRN

# of Institutions

182

Shares Held

71.1M

Call Options Held

183K

Put Options Held

66.7K

View Full List

About AMARIN CORP PLCUK

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $246M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

More about AMRN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account